Evidence map›Paper›PMID 41808040›Full record

ArticleBMC microbiology2026

A temperate phage encoding a catalytically active endolysin: characterization of phage P7869 and its Lys7869 against Pseudomonas aeruginosa.

Jiao Feng, Xuexue Wang, Liangyu Wang, Yuming Zhang, Xiaogang Cui, Yan Meng, Xiaoxia Zhou, Changxin Wu, Chenrui Hou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiao Feng *Institutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China. fengjiao-1219@163.com.
Xuexue Wang *Institutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Liangyu WangInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Yuming ZhangInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Xiaogang CuiInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Yan MengInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Xiaoxia ZhouInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Changxin WuInstitutes of Biomedical Sciences, Biomedical and Health Laboratory in Shanxi Province, Shanxi University, Taiyuan, 030006, China.
Chenrui HouShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China. houchenrui@sxbqeh.com.cn.

Funding

National Natural Science Foundation of China 82002207
6 · The paper itself

Abstract

backgroundPseudomonas aeruginosa poses significant therapeutic challenges due to its acquired and innate resistance mechanisms. Bacteriophages and their purified lysis proteins have emerged as promising alternatives for combating P. aeruginosa infections.

methodsPhage P7869 was isolated from hospital sewage and characterized. Whole-genome sequencing was conducted to elucidate the genomic features of P7869. The recombinant endolysin Lys7869 was expressed and purified using a prokaryotic system, and its stability, minimum inhibitory concentration and antimicrobial spectrum were assessed.

resultsP7869 exhibited a narrow host range and high stability. Genomic analysis confirmed its temperate lifestyle, yet its recombinant endolysin, Lys7869, demonstrated therapeutic potential. Lys7869 demonstrated high stability across a broad range (pH 4–7, 4–50 °C), making it suitable for diverse formulation and storage conditions. It exhibited potent activity with a minimum inhibitory concentration of 500 ng/mL. Lys7869 displayed a broader antimicrobial spectrum against chloroform-permeabilized Gram-negative pathogens, suggesting its potential as a versatile agent to combat various multidrug-resistant strains.

conclusionsThis study identified a novel temperate phage, P7869, and highlights its endolysin Lys7869 as a highly promising antibacterial agent. These findings lay a critical foundation for protein engineering efforts to enhance its outer-membrane penetration and create next-generation enzybiotics against multidrug-resistant Pseudomonas aeruginosa infections.

Indexed as

EndopeptidasesPseudomonas aeruginosaPseudomonas PhagesAnti-Bacterial AgentsGenome, ViralHost SpecificityHydrogen-Ion ConcentrationMicrobial Sensitivity TestsPseudomonas InfectionsRecombinant ProteinsTemperatureWhole Genome SequencingAnti-Bacterial AgentsendolysinEndopeptidasesRecombinant ProteinsBacteriophageEndolysinEnzyme activityPseudomonas aeruginosa

Identifiers

PMID41808040
PMCPMC13088612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.